ODYSSEY OPTIONS I and II - ODYSSEY OPTIONS I and II

Description:

The current trial sought to study the safety and efficacy of alirocumab, a PCSK9 inhibitor, compared with other lipid control strategies in patients who had low-density lipoprotein cholesterol (LDL-C) levels above goal with coronary heart disease/risk equivalents.